In early January, Bausch + Lomb received FDA approval for its Crystalsert 2.6 injector, designed for use with the entire diopter range of Crystalens and Trulign toric intraocular lenses. According to Bausch + Lomb, the Crystalsert allows for smooth and easy lens delivery through an incision as small as 2.6 mm.

The Crystalsert features an oval-shaped tip, which B+L says allows for easy wound entry and helps prevent tissue snagging.The tip of the device also features a straight delivery channel to help reach the capsular bag without stretching the wound. In addition, the Crystalsert features a haptic guide and modified plunger tip to support the leading and trailing haptics during surgery.

The Crystalsert delivery system is a sterile, disposable plastic device, with a small pathway in which the lens can be placed into the eye in one continuous motion, B+L says. It is designed for single use only.

For more information on Bausch + Lomb’s Crystalsert, visit

CooperVision’s MyDay Toric
CooperVision recently announced the introduction of its MyDay toric daily disposable contact lenses in the United States, combining the design features of the Biofinity toric with the “smart silicone” chemistry of MyDay.

This new premium silicone hydrogel one-day lens brings together the advantages of silicone hydrogel, unc
ompromised comfort and handling, and lens stability and visual acuity, CooperVision claims.

MyDay toric lenses are currently available in sphere powers from plano to -6 D (in 0.25-D steps), and -6 to -10 D (in 0.50-D steps), with cylinder options of -0.75 D, -1.25 D and -1.75 D in axes of 10, 20, 70, 80, 90, 100, 110, 160, 170 and 180 degrees, and -2.25 D in axes of 10, 20, 90, 160, 170 and 180 degrees. CooperVision says plus powers will be added soon. MyDay toric lenses have a base curve of 8.6 mm and a diameter of 14.5 mm.

For more information on CooperVision’s MyDay toric, visit

Bausch + Lomb’s Lumify
In late December, Bausch + Lomb received FDA approval for Lumify (brimonidine tartrate ophthalmic solution 0.025%). This is the first over-the-counter eye drop developed with low-dose brimonidine tartrate for the treatment of ocular redness. Brimonidine, first approved by the FDA in 1996 for intraocular pressure reduction in glaucoma patients, is available at higher doses in prescription eye-care products.

Low-dose brimonidine, the active ingredient in Lumify, selectively constricts veins in the eye, increasing the availability of oxygen to surrounding tissue, reducing the potential risk of side effects associated with nonselective redness-relieving eye drops to treat ocular redness, Bausch + Lomb claims. Lumify is expected to be available in the second quarter of 2018.

For more information on Lumify, visit